FY2025 EPS Estimates for Teladoc Health Decreased by Analyst
Zacks Research has lowered its FY2025 earnings estimates for Teladoc Health (NYSE:TDOC), now predicting a loss of ($0.90) per share, down from a previous estimate of ($0.83). The firm maintains a "Hold" rating on the stock, while other analysts have also issued "neutral" or "market perform" ratings with price target reductions. The article also details recent stock performance, institutional holdings, and insider trading activity for Teladoc Health.
Teladoc Q4 Earnings: Can Integrated Care Strength Save Profits?
Teladoc Health (TDOC) is projected to report fourth-quarter 2025 results with an estimated loss of 19 cents per share on revenues of $633.91 million. While the company's Q4 earnings estimate has improved and anticipates a significant year-over-year EPS improvement for 2025, revenue is expected to decline. The strength in U.S. Integrated Care membership and adjusted EBITDA from this segment is a positive, but declines in access fees, U.S. operations revenue, and BetterHelp contributions pose challenges.
Teladoc Q4 Earnings: Can Integrated Care Strength Save Profits?
Teladoc Health (TDOC) is projected to report its Q4 2025 earnings on February 25, 2026, with a Zacks Consensus Estimate of a loss of 19 cents per share on revenues of $633.91 million. While adjusted EPS is expected to show significant year-over-year improvement, revenue is anticipated to decline. The company's U.S. Integrated Care segment shows promising growth, potentially offsetting declines in BetterHelp and overall access fees.
Is Teladoc Health (TDOC) Stock Undervalued Right Now?
Teladoc Health (TDOC) stock appears undervalued according to Zacks' Style Scores system, earning a Zacks Rank #2 (Buy) and an 'A' grade for Value. The article highlights TDOC's favorable Price-to-Book (P/B) ratio of 0.99 against an industry average of 2.09, and a Price-to-Cash Flow (P/CF) ratio of 6.35 compared to the industry average of 13.44. These metrics, coupled with a strong earnings outlook, suggest that Teladoc Health is a compelling value investment.
Teladoc Q4 Earnings: Can Integrated Care Strength Save Profits?
Teladoc Health (TDOC) is projected to report its Q4 2025 earnings on February 25, 2026, with analysts expecting a loss of 19 cents per share on revenues of $633.91 million. While the company has a mixed earnings beat history, its U.S. Integrated Care segment is anticipated to show significant growth in members and adjusted EBITDA, potentially offsetting declines in other areas like BetterHelp and overall access fees. The article also provides a comparison with other medical sector companies, CVS Health and Doximity.
Teladoc Health, Inc. Appoints Michael S. Smith as Director and Audit, Nominating and Corporate Governance Committees, Effective February 18, 2026
Teladoc Health, Inc. has appointed Michael S. Smith to its Board of Directors, as well as to its audit and nominating and corporate governance committees, effective February 18, 2026. Smith, who brings extensive experience in financial management and strategic transformation from Voya Financial and Lincoln Financial, has been deemed an independent director and an "audit committee financial expert." His appointment follows the retirements of Eric Evans and Thomas McKinley from the board.
BofA Lowers Teladoc (TDOC) PT on Peer Multiple Compression, Soft Sensor Tower Trends
Bank of America lowered its price target for Teladoc (TDOC) to $7 from $7.50, citing peer multiple compression and soft Sensor Tower trends suggesting Q4 2025 revenue might miss the midpoint of Teladoc's guidance. This follows similar price target reductions by Goldman Sachs and Citi earlier this year due to declines in MedTech and Healthcare IT stocks and a difficult 2025 for the health tech industry. Despite potential, the article suggests other AI stocks might offer greater upside and less risk than TDOC.
Teladoc Health Appoints Michael Smith, Experienced Insurance and Financial Services Executive, to Its Board of Directors
Teladoc Health announced the appointment of Michael Smith to its board of directors. Smith brings over three decades of experience in financial management and strategic transformation, having served as Vice Chair and CFO of Voya Financial and currently as Executive Chairman of Talcott Financial Group. He will serve on the board’s audit and nominating and corporate governance committees, contributing to the company's long-term growth and strategic focus.
Teladoc Health Appoints Michael Smith to Board of Directors
Teladoc Health has appointed Michael Smith to its board of directors, bringing more than 30 years of experience in financial management and strategic transformation, following the retirements of two previous board members. Smith's expertise in enterprise transformations is expected to align with Teladoc's mission to innovate in virtual care. The company is set to announce its fourth-quarter 2025 results on February 25, 2026.
BofA Lowers Teladoc (TDOC) PT on Peer Multiple Compression, Soft Sensor Tower Trends
Bank of America (BofA) has lowered its price target for Teladoc Health Inc. (NYSE: TDOC) to $7 from $7.50, maintaining a Neutral rating. This adjustment is due to peer multiple compression and Sensor Tower trends suggesting Q4 2025 revenue might align with consensus but fall below Teladoc's guidance midpoint. Goldman Sachs and Citi also recently reduced their price targets for TDOC, citing industry declines and a cautious outlook for the health tech sector.
Teladoc Health Appoints Michael Smith, Experienced Insurance and Financial Services Executive, to Its Board of Directors
Teladoc Health (NYSE: TDOC) has appointed Michael Smith, a seasoned insurance and financial services executive, to its board of directors. Smith brings over three decades of leadership experience in financial management and strategic transformation, having served as former Vice Chair and CFO of Voya Financial and currently as Executive Chairman of Talcott Financial Group. His expertise is expected to be instrumental as Teladoc Health continues to scale and innovate in the virtual care market.
Teladoc Health Appoints Michael Smith, Experienced Insurance and Financial Services Executive, to Its Board of Directors
Teladoc Health announced the appointment of Michael Smith to its board of directors. Smith brings over three decades of leadership experience in financial management and strategic transformation, having served as former Vice Chair and CFO of Voya Financial and currently as Executive Chairman of Talcott Financial Group. He will serve on the board's audit and nominating and corporate governance committees, with a focus on accelerating the company's strategic growth.
Teladoc Health, Inc. (TDOC) Stock Analysis: Unpacking a 92% Potential Upside for Investors
Teladoc Health (TDOC) offers a potential 92.08% upside from its current stock price of $4.65, despite facing challenges like declining revenues and negative earnings. The company, a leader in virtual healthcare with its Integrated Care and BetterHelp segments, has a market cap of $825.25 million and a substantial free cash flow of over $206 million. Analyst ratings show cautious optimism, with 5 buy and 22 hold recommendations averaging an $8.93 target price, while technical indicators suggest the stock is oversold, potentially presenting a high-risk, high-reward opportunity for long-term investors.
Telemedicine & Digital Health Research Report 2026: A $180 Billion Market by 2031 from $85.5 Billion in 2025 with Teladoc Health, Amwell, Philips, Siemens Healthineers, GE, Medtronic, Oracle Leading
The Telemedicine & Digital Health market is projected to grow from $85.5 billion in 2025 to $180 billion by 2031, with a CAGR of 13.21%. This growth is driven by the integration of AI, ML, and IoT, expanded digital infrastructure, and rising smartphone penetration, enhancing access and personalized care. North America currently leads the market, supported by favorable telehealth policies and the dominance of cloud-based solutions.
North America Medical Second Opinion Market is expected to reach
The North America medical second opinion market is projected to reach US$ 6.09 Billion by 2033, growing at a CAGR of 13.3% from 2025 to 2033, driven largely by telehealth expansion. The market report highlights key players, discusses recent developments like AI-assisted platforms and cross-border programs, and provides a detailed segmentation and regional analysis across the US, Canada, and Mexico. The increasing adoption of these services is attributed to informed decision-making, especially in complex medical cases.
Teladoc Announces Retirement of Long-Serving Board Director
Teladoc Health, Inc. announced the retirement of Thomas G. McKinley from its board of directors, effective February 20, 2026. McKinley, who has served since 2009, is stepping down for personal reasons, not due to any disagreements with management. Despite some positive insights like exceeding revenue guidance, Teladoc's stock faces significant financial and technical challenges, with analysts currently rating it as a "Hold."
Teladoc Announces Retirement of Long-Serving Board Director
Teladoc Health announced that long-serving board member Thomas G. McKinley will retire effective February 20, 2026, due to personal reasons. McKinley has been a director since 2009, and his departure is not related to any disagreement with management. Analysts currently rate TDOC stock as a Hold with a $5.50 price target, while TipRanks' AI Analyst assesses it as Neutral due to persistent losses and negative valuation metrics.
Teladoc Health expands virtual care access through HealthKey partnership
Teladoc Health has partnered with HealthKey to expand access to virtual care services, particularly in underserved areas. This collaboration aims to leverage Teladoc Health's technology to address healthcare disparities and improve overall access and equity in medical support. The initiative underscores the growing importance of telehealth in bridging gaps within the healthcare system.
HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell?
Hims & Hers Health Inc. (HIMS) stock has declined 55.8% in the past three months, underperforming its industry and the broader market. Despite robust top-line growth and strategic expansions into new health categories, the company faces challenges including weak bottom-line results, margin contraction, competitive pressures, and significant regulatory and legal scrutiny over its compounded GLP-1 drugs. Given these factors, particularly the "Strong Sell" Zacks Rank, the article suggests trimming exposure to HIMS until visibility improves.
Telemedicine Market to Reach US$ 488.89 Billion by 2033 at 16.8% CAGR | North America Leads with 39% Share | Key Players Include Teladoc Health, Philips, GE HealthCare, Siemens Healthineers, American Well
The global telemedicine market is projected to grow significantly from US$ 129.70 billion in 2024 to US$ 488.89 billion by 2033, exhibiting a CAGR of 16.8%. This growth is fueled by increasing demand for remote healthcare, technological advancements, and supportive government policies. North America currently leads the market with a 39% share, while key players include Teladoc Health, Philips, GE HealthCare, Siemens Healthineers, and American Well.
Teladoc Health, Inc. (NYSE:TDOC) Given Average Rating of "Hold" by Analysts
Sixteen brokerages have issued an average "Hold" rating for Teladoc Health, Inc. (NYSE:TDOC), with a 12-month average target price of $9.12. Insider selling occurred in the last quarter, with CEO Charles Divita III among those who sold shares. The stock recently opened at $4.74 and has a market cap of approximately $840 million.
Digital Health Market to Reach US$ 1,907.21 Billion by 2033,
The global Digital Health Market is projected to grow from US$ 361.65 billion in 2024 to US$ 1,907.21 billion by 2033, demonstrating a CAGR of 20.6% during the forecast period. This growth is primarily driven by increasing adoption of digital healthcare solutions for improved patient outcomes, accessibility, and operational efficiency, although privacy and data security concerns remain a significant restraint. Key players like Philips, Medtronic, and Apple are contributing to market expansion through innovations in telehealth, remote monitoring, and AI-driven diagnostics.
Allianz Asset Management GmbH Grows Holdings in Teladoc Health, Inc. $TDOC
Allianz Asset Management GmbH significantly increased its stake in Teladoc Health, Inc. by 189.2% in the third quarter of 2025, now holding 1,619,391 shares valued at approximately $12.52 million. Despite this increased institutional interest, Teladoc's stock is trading near its 52-week low, and analysts maintain an average "Hold" rating with a consensus price target of $9.12 following recent downgrades. Institutional investors collectively own 76.82% of the company's stock, while insiders sold shares worth about $251,684 in the last quarter.
Online Doctor Consultation Market Set for Explosive Growth
The Global Online Doctor Consultation Market is projected to experience explosive growth, reaching US$ 47.29 billion by 2033 from US$ 12.05 billion in 2024, driven by increased demand for convenient healthcare, digital health adoption, and technological advancements. North America currently holds the largest market share, while the Asia Pacific region is expected to show the fastest growth. Key players like Teladoc Health, PlushCare, and American Well are innovating with AI-enhanced platforms, wearable integrations, and expanded virtual care services to capture market opportunities despite challenges related to data privacy and the digital divide.
Teladoc (TDOC) Sees Increased Bullish Activity in Options Market
Teladoc (TDOC) is experiencing significant bullish activity in its options market, with a notable volume of call options traded and a low Put/Call Ratio. Despite this, the company's financial health shows challenges, including a negative ROE and a Z-Score indicating financial distress. Valuation metrics suggest the stock may be undervalued, trading near historical lows for its P/S and P/B ratios.
United States Telehealth Solutions Market to Grow at 32.1% CAGR
The United States Telehealth Solutions Market is projected to grow at a Compound Annual Growth Rate (CAGR) of 32.1% between 2024 and 2031, with North America being the largest market. Key players like Teladoc Health Inc., American Well, and MDLIVE Inc. are driving innovations like AI-powered platforms and remote monitoring. The market's growth is fueled by technological advancements, increased adoption due to the COVID-19 pandemic, and the rising demand for cost-effective, accessible healthcare solutions, despite challenges such as healthcare fraud and behavioral adoption barriers.
Teladoc Health to Announce Fourth Quarter 2025 Financial Results
Teladoc Health (NYSE: TDOC) will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market closes. The company will host a conference call at 5:00 p.m. ET on the same day to discuss the results, with details provided for both U.S. and international participants. A live audio webcast and replay will also be available on Teladoc Health's investor relations website.
Teladoc Health, Inc. $TDOC Shares Sold by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd significantly reduced its stake in Teladoc Health ($TDOC) by 92% in Q3 2025, selling 287,570 shares while retaining 24,990. Despite this divestment, several other institutional investors, including Bridgeway Capital Management and Allianz Asset Management, either initiated new positions or substantially increased their holdings, leading to institutional ownership now standing at 76.82%. The stock is currently trading near its 52-week low with a "Hold" consensus rating from analysts and an average target price of $9.12, and corporate insiders have been net sellers.
Teladoc Health, Inc.'s (NYSE:TDOC) 28% Dip In Price Shows Sentiment Is Matching Revenues
Teladoc Health's (NYSE:TDOC) stock price has fallen 28% recently, bringing its price-to-sales (P/S) ratio to 0.4x, which is significantly below the industry average. This low P/S ratio reflects investor sentiment aligning with the company's declining revenue growth, which saw a 2.4% decrease last year and is forecast to grow at only 2.1% annually over the next three years, compared to the industry's projected 13% growth. Analysts suggest that the future limited growth outlook is the main reason for the depressed stock price and P/S ratio.
Teladoc Health to Announce Fourth Quarter 2025 Financial Results
Teladoc Health Inc. announced that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after market close. The company will also host a conference call at 5:00 p.m. ET on the same day to review these results. Details for accessing the conference call via dialing or webcast are provided for interested participants.
Teladoc Health drives confidence in hypertension care
Teladoc Health is actively working to improve hypertension care through its telemedicine services. The company offers daily monitoring and personalized guidance, which has proven effective in helping patients like Corinne significantly lower their blood pressure and increase their confidence in managing their condition. This approach highlights Teladoc Health's commitment to enhancing patient outcomes for chronic conditions via virtual healthcare.
Teladoc Health to Announce Fourth Quarter 2025 Financial Results
Teladoc Health Inc. (NYSE: TDOC) announced it will release its fourth-quarter 2025 financial results on Wednesday, February 25, 2026, after the market closes. The company will host a conference call at 5:00 p.m. ET on the same day to discuss the results. Details for accessing the conference call via dialing or live audio webcast are provided.
Teladoc Health to Announce Fourth Quarter 2025 Financial Results
Teladoc Health Inc. (NYSE: TDOC) announced it will release its fourth-quarter 2025 financial results on Wednesday, February 25, 2026, after the market closes. The company will host a conference call at 5:00 p.m. ET on the same day to discuss the results, with details provided for both U.S. and international participants, along with an online webcast option. Teladoc Health, a leader in virtual care, emphasizes its role in transforming healthcare through its platform and partnerships.
Digital Therapeutics Revolution Transforming Chronic Care with Technology-Driven Solutions
The digital therapeutics (DTx) industry is rapidly growing, offering technology-driven solutions for managing chronic conditions and mental health. Regulatory bodies globally are increasingly approving DTx products, and clinical trials demonstrate their real-world effectiveness. The market is projected to grow significantly, driven by rising chronic disease burdens and advancements in AI and data analytics, making DTx an integral part of future healthcare strategies.
Lacklustre Performance Is Driving Teladoc Health, Inc.'s (NYSE:TDOC) 28% Price Drop
Teladoc Health, Inc. (NYSE:TDOC) shares have fallen 28% in the last month, contributing to a 51% loss over the past year due to a decline in revenue. The company's low price-to-sales (P/S) ratio of 0.4x, significantly below the industry average, reflects investor concerns about its lacklustre growth prospects. Analysts forecast Teladoc Health's revenue to grow by only 2.1% annually over the next three years, compared to the industry's projected 13% growth, which further justifies its current valuation.
Jim Cramer on Teladoc: "I Don't See Any Reason to Own It"
Jim Cramer advised a caller to sell Teladoc Health Inc. (NYSE: TDOC) stock, stating he sees no reason to own it, especially given the caller's significant losses. He noted that many companies operate in the same crowded virtual medical care business. The article also suggests that while Teladoc has potential, other AI stocks might offer better upside with less risk.
Jim Cramer on Teladoc: “I Don’t See Any Reason to Own It”
Jim Cramer strongly advised against owning Teladoc Health (NYSE: TDOC), telling a caller who had lost nearly 96% on the stock to "just get rid of it." He stated there's no reason to own it given the competition in the virtual medical care business. The article also suggests that while Teladoc carries risk and potential, AI stocks may offer greater returns in a shorter time frame.
Teladoc Health, Inc.'s (NYSE:TDOC) 28% Dip In Price Shows Sentiment Is Matching Revenues
Teladoc Health's stock price has fallen 28% in the last month, contributing to a 51% decline over the past year. Its low price-to-sales (P/S) ratio of 0.4x, compared to an industry average of 2.2x, reflects investor sentiment due to declining revenue and a projected future growth rate of only 2.1% per year, significantly trailing the industry's 13%. This suggests that the market has low expectations for Teladoc Health's future performance.
The Truth About Teladoc Health Inc: Is TDOC’s Telehealth Empire Still Worth Your Money?
Teladoc Health Inc. (TDOC) has seen its stock price fall significantly since its pandemic peak, leading to questions about its future. While the company's virtual care services, particularly for mental health and chronic conditions, are still considered valuable and convenient, it faces increasing competition from other telehealth providers and large healthcare systems. The article suggests that Teladoc is now an infrastructure play rather than a hyper-growth stock, suitable for patient, high-risk investors interested in long-term telehealth adoption rather than quick gains or viral trends.
Teladoc Health (TDOC) Is Down 13.9% After Medicare Tightens Telehealth Coverage - What's Changed
Teladoc Health (TDOC) experienced a 13.9% stock price drop after Medicare announced a sharp scale-back in telehealth coverage, primarily affecting rural areas and specific mental health uses. While Teladoc's revenue is largely tied to commercial health plans, this policy shift amplifies concerns regarding its BetterHelp user declines and overall path to profitability. The article explores how this reimbursement rollback, alongside BetterHelp headwinds, impacts Teladoc's investment outlook and market valuation.
Teladoc Health Is One of the 2021 TIME100 Most Influential Companies
Teladoc Health has been recognized as one of the 2021 TIME100 Most Influential Companies for its role in updating telemedicine. The company experienced a significant increase in virtual medical visits in 2020, facilitating remote care during the COVID-19 pandemic. Teladoc provides various nonemergency services and is integrating data uploads from connected medical devices to further enhance its offerings.
Teladoc Health (TDOC) Is Down 13.9% After Medicare Tightens Telehealth Coverage - What's Changed
Teladoc Health (TDOC) shares dropped 13.9% following Medicare's decision to significantly reduce telehealth coverage, primarily to rural areas and for specific mental health services. While Teladoc's revenue largely stems from commercial health plans, this policy shift exacerbates concerns about declining BetterHelp users, increased competition, and its path to profitability. The market's low price-to-sales multiple suggests skepticism regarding Teladoc's ability to achieve sustained profitability, making the reimbursement changes a critical factor in its investment narrative.
A Look At Teladoc Health’s Valuation As Medicare Telehealth Policy And Options Activity Drive Uncertainty
Teladoc Health (TDOC) is facing scrutiny due to Medicare's planned rollback of broad telehealth coverage and increased options trading activity. Despite a significant share price decline, the company is considered undervalued with a narrative fair value of $9.13 compared to its current $5.45 trading price, driven by product innovation and growing demand for digital chronic disease management. However, potential shifts in BetterHelp's revenue model or impacts from Medicare policy changes could affect future earnings and virtual visit volumes.
A Look At Teladoc Health’s Valuation As Medicare Telehealth Policy And Options Activity Drive Uncertainty
Teladoc Health (TDOC) is facing increased scrutiny due to upcoming Medicare policy changes regarding telehealth coverage and a surge in bullish options trading activity. Despite being undervalued according to Simply Wall St's narrative fair value of $9.13, regulatory risks and potential impacts on earnings from BetterHelp's shift to insurance revenue could challenge its growth. The article suggests investors consider Teladoc's current valuation, analyst discounts, and key risks before making investment decisions, while also offering tools for personalized research and exploring other virtual care and healthcare AI investment opportunities.
Chuck Divita on why 2026 is Teladoc’s ‘execution year’
Teladoc Health CEO Chuck Divita has declared 2026 an "execution year" for the company, focusing on sustainable long-term growth following a period of strategic shifts. Key initiatives include expanding insurance acceptance for its BetterHelp mental health platform, executing a targeted M&A strategy to accelerate growth in integrated care and international markets, and leveraging AI for efficiency to support clinicians rather than replace them. Divita emphasized that M&A will continue to be a lever aligned with these priorities, and AI will primarily assist with administrative tasks and data analysis for personalized care.
Teleoncology Market to Reach US$ 15.03 Billion by 2032 at 15.7%
The teleoncology market is projected to reach US$ 15.03 billion by 2032, growing at a CAGR of 15.7% from its 2024 valuation of US$ 4.70 billion. This significant growth is attributed to the increasing global cancer burden, a shortage of oncology specialists, and the rising adoption of telehealth platforms for remote cancer care. North America currently leads the market with a 41% share, driven by its robust telehealth infrastructure, favorable reimbursement policies, and advanced oncology care systems.
Medicare Telehealth Uncertainty And BetterHelp Weakness Test Teladoc Valuation
Analysts are concerned about Teladoc Health's revenue mix due to expiring Medicare telehealth reimbursement provisions and softer consumer sentiment impacting BetterHelp's monthly active users. These factors are drawing attention to Teladoc's demand outlook for both medical and mental health services. Investors will likely focus on the resilience of demand for virtual care and Teladoc's strategies to adjust to potential reimbursement changes and user base pressure.
Why Teladoc (TDOC) Shares Are Plunging Today
Teladoc Health (TDOC) shares dropped 5.6% after BofA Securities lowered its price target to $7.00 due to concerns over expiring Medicare telehealth reimbursements and a significant drop in monthly active users for its BetterHelp service. Analysts also noted weak consumer sentiment contributing to the pressure. The company's shares have been highly volatile and are down 16.1% year-to-date, trading significantly below its 52-week high.
Are Telehealth Stocks Set to Tumble in 2026?
Telehealth stocks, particularly Teladoc Health and Doximity, are predicted to face challenges in 2026 due to impending changes in Medicare reimbursement policies. As of January 31, Medicare will largely restrict coverage for at-home telehealth services in non-rural areas, significantly impacting demand. While Teladoc Health, a pure-play telehealth company, is expected to be severely affected, Doximity, with its broader platform for physicians, might fare slightly better but still faces issues with slowing growth and market saturation.
Teladoc stock hits 52-week low at 6.03 USD
Teladoc (TDOC) stock has fallen to a new 52-week low of $6.03, representing a 38.39% decline over the past year. Despite ongoing challenges in the digital health sector and a recent revenue decline, InvestingPro data suggests the company is undervalued with a strong free cash flow yield. Analysts have adjusted price targets, and Teladoc is enhancing its services while investors await upcoming earnings results to assess future performance.
